Ritholtz Wealth Management Buys Shares of 12,233 Pro-Dex, Inc. (NASDAQ:PDEX)

Ritholtz Wealth Management purchased a new stake in Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 12,233 shares of the medical instruments supplier's stock, valued at approximately $572,000. Ritholtz Wealth Management owned approximately 0.38% of Pro-Dex as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. FMR LLC boosted its stake in shares of Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock valued at $119,000 after purchasing an additional 1,028 shares in the last quarter. Renaissance Technologies LLC boosted its position in Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier's stock valued at $240,000 after acquiring an additional 900 shares in the last quarter. Bard Associates Inc. grew its holdings in shares of Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier's stock worth $406,000 after acquiring an additional 2,031 shares during the period. JPMorgan Chase & Co. raised its position in shares of Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier's stock worth $740,000 after acquiring an additional 529 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier's stock valued at $819,000 after purchasing an additional 2,296 shares during the period. 15.28% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Alisha Charlton sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $40.02, for a total transaction of $40,020.00. Following the completion of the sale, the chief financial officer now owns 15,339 shares of the company's stock, valued at $613,866.78. This trade represents a 6.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Raymond E. Cabillot sold 6,820 shares of the company's stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $44.86, for a total value of $305,945.20. Following the completion of the transaction, the director now directly owns 344,683 shares in the company, valued at $15,462,479.38. This trade represents a 1.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,523 shares of company stock valued at $657,266. 47.50% of the stock is currently owned by corporate insiders.

Pro-Dex Stock Down 0.8 %

Shares of PDEX traded down $0.35 during mid-day trading on Tuesday, reaching $44.00. The company had a trading volume of 25,400 shares, compared to its average volume of 28,077. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.94 and a current ratio of 3.41. The company has a market capitalization of $143.44 million, a price-to-earnings ratio of 28.60 and a beta of 0.56. The firm has a 50-day moving average price of $48.20 and a 200 day moving average price of $33.25. Pro-Dex, Inc. has a 52 week low of $16.18 and a 52 week high of $59.60.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on PDEX shares. StockNews.com raised Pro-Dex from a "buy" rating to a "strong-buy" rating in a research note on Saturday, December 14th. Ascendiant Capital Markets increased their price target on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a "buy" rating in a research note on Monday, November 11th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.